Why Eli Lilly Stock Climbed to a New All-Time High Today
The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.
Why Eli Lilly Stock Climbed to a New All-Time High Today
Overview
Shares of Eli Lilly (NYSE: LLY) rose to a record high on Monday after the medicine maker announced positive clinical trial results for its next-generation weight loss drug.
Image source: Getty Images.
Retatrutide, Eli Lilly's investigational once-weekly injectable medication, targets three metabolic hormones to suppress appetite, control blood sugar, and support fat loss.
Details
Source
Originally published at www.fool.com.
Related Articles
- 51% of U.S. adults say the American Dream is out of reach for most people right now: CNBC survey
- A massive 16% market swing just rocked South Korea over 24 hours. The retail ‘ants’ holding the wheel are driving dangerously.
- I’m 60, retired with $3 million. My fiancée, 55, has $1 million but plans to work for the next 10 years. Are we compatible?
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
